Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.

The European respiratory journal - 1 Jun 2016

Dilokthornsakul Piyameth, Hansen Ryan N, Campbell Jonathan D

Abstract excerpt

Ivacaftor, a breakthrough treatment for cystic fibrosis (CF) patients with the G551D genetic mutation, lacks long-term clinical and cost projections. This study forecasted outcomes and cost by comparing ivacaftor plus usual care versus usual care alone.A lifetime Markov model was conducted from a US payer perspective. The model consisted of five health states: 1) forced expiratory volume in 1 s (FEV1) % pred...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Cost-Benefit Analysis
Share to Drug Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Forced Expiratory Volume

Share to Health Status

Share to Lung Transplantation

Share to Quality-Adjusted Life Years

Share to Respiratory Function Tests

Source

Identifiers

PMID: 27126691
DOI: 10.1183/13993003.01444-2015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.PMID 27126691Read ↗

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.Semantic proximity Read ↗

Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation.Semantic proximity Read ↗

Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.Semantic proximity Read ↗

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity Read ↗

Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.Semantic proximity Read ↗

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor.Semantic proximity Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.Semantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.